EFFICACY AND TOXICITY OF A NEW SHORT-TERM HIGH INTENSIVE PROTOCOL BL-M-04 FOR ADULT PATIENTS WITH BURKITT LYMPHOMA: INTERMEDIATE RESULTS

被引：0
|
作者：
Baryakh, E. A. [1 ]
Kravchenco, S. K. [1 ]
Kremenetskaja, A. M. [1 ]
Zvonkov, E. E. [1 ]
Vorobjov, A. I. [1 ]
机构：
[1] Russian Hematol Sci Ctr, Moscow, Russia
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2008年 / 93卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0988
引用
收藏
页码：393 / 394
页数：2
相关论文
共 39 条
  • [21] Intensive chemotherapy for Burkitt's lymphoma and leukemia:: Similar results for HIV positive and negative adult patients treated with PETHEMA ALL3/97 protocol.
    Ribera, JM
    Oriol, A
    Esteve, J
    Rovira, M
    Brunet, S
    Sierra, J
    Sanz, MA
    Martín, G
    García-Boyero, R
    Peñarrubia, MD
    Abella, E
    Besalduch, J
    Sánchez-Delgado, M
    Fernandez-Abellán, P
    Pérez, I
    Deben, G
    Borrego, D
    Guinea, J
    Montserrat, E
    Feliu, E
    BLOOD, 2001, 98 (11) : 343A - 343A
  • [22] Feasibility and Toxicity of a Modified Dose Intensive R- CODOX-M/IVAC for HIV-Associated Burkitt and Atypical Burkitt Lymphoma(BL): Preliminary Results of a Prospective Multicenter Phase II Trial of the AIDS Malignancy Consortium (AMC)
    Noy, Ariela
    Kaplan, Lawrence
    Lee, Jeannette
    BLOOD, 2009, 114 (22) : 1415 - 1416
  • [23] Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL
    Dai Maruyama
    Takashi Watanabe
    Akiko Miyagi Maeshima
    Junko Nomoto
    Hirokazu Taniguchi
    Teruhisa Azuma
    Masakazu Mori
    Wataru Munakata
    Sung-Won Kim
    Yukio Kobayashi
    Yoshihiro Matsuno
    Kensei Tobinai
    International Journal of Hematology, 2010, 92 : 732 - 743
  • [24] Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL
    Maruyama, Dai
    Watanabe, Takashi
    Maeshima, Akiko Miyagi
    Nomoto, Junko
    Taniguchi, Hirokazu
    Azuma, Teruhisa
    Mori, Masakazu
    Munakata, Wataru
    Kim, Sung-Won
    Kobayashi, Yukio
    Matsuno, Yoshihiro
    Tobinai, Kensei
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2010, 92 (05) : 732 - 743
  • [25] SHORT-TERM WEEKLY CHEMOTHERAPY FOLLOWED BY HIGH-DOSE THERAPY WITH AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR LYMPHOBLASTIC AND BURKITT LYMPHOMAS IN ADULT PATIENTS
    JOST, LM
    JACKY, E
    DOMMANNSCHERRER, C
    HONEGGER, HP
    MAURER, R
    SAUTER, C
    STAHEL, RA
    ANNALS OF ONCOLOGY, 1995, 6 (05) : 445 - 451
  • [26] Proton Irradiation using the Pencil Beam Scanning Technology for Patients with mediastinal Hodgkin's Lymphoma: acute Toxicity and short-term therapeutic Results
    Dedeckova, K.
    Kubes, J.
    Zapletalova, S.
    Mocikova, H.
    Markova, J.
    Gaherova, L.
    Kaliska, L.
    Andrlik, M.
    Vondracek, V.
    Koren, J.
    Vackova, B.
    Feltl, D.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2019, 195 : S22 - S22
  • [27] An investigation of the efficacy and safety of remifentanil for the provision of optimal sedation in adult ICU patients requiring short-term mechanical ventilation: preliminary results
    B Muellejans
    A Lopez
    MH Cross
    C Bonome
    L Morrison
    A Kirkham
    Critical Care, 5 (Suppl 1):
  • [28] HIGH EFFICACY OF SHORT-TERM QUININE-ANTIBIOTIC COMBINATIONS FOR TREATING ADULT MALARIA PATIENTS IN AN AREA IN WHICH MALARIA IS HYPERENDEMIC
    METZGER, W
    MORDMULLER, B
    GRANINGER, W
    BIENZLE, U
    KREMSNER, PG
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (01) : 245 - 246
  • [29] A Modified Dose Intensive R- CODOX-M/IVAC For HIV-Associated Burkitt and Atypical Burkitt Lymphoma(BL) Demonstrates High Cure Rates and Low Toxicity: Prospective Multicenter Phase II Trial Of The AIDS Malignancy Consortium (AMC 048)
    Noy, Ariela
    Kaplan, Lawrence
    Lee, Jeannette Y.
    BLOOD, 2013, 122 (21)
  • [30] Incorporation of rituximab and liposomal doxorubicin into CODOX-m/IVAC for HIV-negative and HIV-positive adult patients (pts) with untreated Burkitt's lymphoma (BL): Preliminary results of a multicenter phase II study
    Gregory, S. A.
    Barr, P. M.
    Nabhan, C.
    Nukala, A.
    Gallot, L.
    Larsen, A.
    Moll, M. Z.
    Smith, S. E.
    Gordon, L. I.
    Evens, A. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
1234